[1]Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments[J]. Lancet, 2015, 386(9990): 281-291.
[2]Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing[J]. Clin Pharmacol Ther, 2011, 90(4): 625-629.
[3]Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting[J]. Blood, 2009, 113(4): 784-792.
[4]Verhoef TI, Redekop WK, Daly AK, et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon[J]. Br J Clin Pharmacol, 2014, 77(4): 626-641.
[5]Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation[J]. Circulation, 2007, 116(22): 2563-2570.
[6]Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives[J]. Thromb Res,2007, 120(1): 1-10.
[7]刘会臣. 手性药物的药代动力学立体选择性及其影响因素研究进展[J]. 中国临床药理学杂志, 2003,8(5): 380-383.
[8]李琳,张炜,沈陈林,等. 阿司匹林与华法林在体肠吸收的相互作用研究[J]. 中国临床药理学与治疗学, 2015,20(5): 486-492.
[9]Shen C, Huang X, Li J, et al. Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs[J]. Xenobiotica, 2016, 46(6): 530-541.
[10]黄晓晖,王夏芹,唐海沁,等. 华法林和阿司匹林联用在大鼠体内的药代动力学研究(英文)[J]. 中国临床药理学与治疗学, 2012,17(2): 189-195.
[11]Niopas I, Toon S, Aarons L, et al. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans[J]. Eur J Clin Pharmacol, 1999, 55(5): 399-404.
[12]Impellizzeri P, Centonze A, Antonuccio P, et al. Utility of a scoring system in the diagnosis of acute appendicitis in pediatric age. A retrospective study[J]. Minerva Chir, 2002, 57(3): 341-346.
[13]Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research[J]. Pharmacogenomics J, 2007, 7(3): 154-179.
[14]De Oliveira AV, De Souza FA, Ribeiro DD, et al. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients[J]. J Thromb Haemost, 2011, 9(10): 2120-2122.
[15]Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors[J]. Pharmacogenomics J, 2004, 4(1): 40-48.
[16]Chai GH, Hu FQ, Sun J, et al. Transport pathways of solid lipid nanoparticles across Madin-Darby canine kidney epithelial cell monolayer[J]. Mol Pharm, 2014, 11(10): 3716-3726.
[17]Wadhera RK, Russell CE, Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose[J]? Circulation, 2014, 130(22): e191-e193.
[18]Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors[J]. Clin Pharmacokinet, 2002, 41(5): 343-370.
[19]Ermer JC, Hicks DR, Wheeler SC, et al. Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin[J]. Clin Pharmacol Ther, 1994, 55(3): 305-316.
[20]Toon S, Trager WF. Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone[J]. J Pharm Sci, 1984, 73(11): 1671-1673.
[21]Lewis RJ, Trager WF. Warfarin metabolism in man: identification of metabolites in urine[J]. J Clin Invest, 1970, 49(5): 907-913.
[22]Lewis RJ, Trager WF, Robinson AJ, et al. Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols[J]. J Lab Clin Med, 1973, 81(6): 925-931.
[23]Gebauer M. Synthesis and structure-activity relationships of novel warfarin derivatives[J]. Bioorg Med Chem, 2007, 15(6): 2414-2420.
[24]Jones DR, Miller GP. Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know[J]. Expert Opin Drug Metab Toxicol, 2011, 7(7): 857-874.
[25]Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes[J]. Pharmacogenetics, 1998, 8(5): 365-373.
[26]Jones DR, Kim SY, Boysen G, et al. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin[J]. Drug Metab Lett, 2010, 4(4): 213-219.
[27]Kaminsky LS, de Morais SM, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe[J]. Mol Pharmacol,1993, 43(2): 234-239.
[28]Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions[J]. Chem Res Toxicol, 1992, 5(1): 54-59.
[29]Zhang Z, Fasco MJ, Huang Z, et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe[J]. Drug Metab Dispos, 1995, 23(12): 1339-1346.
[30]Miller GP. Warfarin therapy: how the less interesting half just got interesting[J]. J Thromb Haemost, 2010, 8(12): 2705-2707.
[31]Ritter JK. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions[J]. Chem Biol Interact, 2000, 129(1/2): 171-193.
[32]Zielinska A, Lichti CF, Bratton S, et al. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases[J]. J Pharmacol Exp Ther, 2008, 324(1): 139-148.
[33]Miller GP, Jones DR, Sullivan SZ, et al. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans[J]. Chem Res Toxicol,2009, 22(7): 1239-1245.
[34]Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions[J]. Arch Intern Med, 2005, 165(10): 1095-1106.
[35]Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature[J]. Pharmacotherapy, 2004, 24(2): 285-290.
[36]Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update[J]. J Thromb Thrombolysis, 2011, 31(3): 326-343.
[37]Dionisio D, Mininni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine[J]. AIDS, 2001, 15(2): 277-278.
[38]陈刚,杨劲,张广钦. 华法林与胺碘酮相互作用研究进展[J]. 中国临床药理学与治疗学, 2017,22(2): 215-221.
[39]Lim MK, Sadarangani P, Chan HL, et al. Complementary and alternative medicine use in multiracial Singapore[J]. Complement Ther Med, 2005, 13(1): 16-24.
[40]Cuzzolin L, Francini-Pesenti F, Zaffani S, et al. Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: a pilot study[J]. Pharmacoepidemiol Drug Saf, 2007, 16(9): 1014-1017.
[41]Ramsay NA, Kenny MW, Davies G, et al. Complimentary and alternative medicine use among patients starting warfarin[J]. Br J Haematol, 2005, 130(5): 777-780.
[42]Wong RS, Cheng G, Chan TY. Use of herbal medicines by patients receiving warfarin[J]. Drug Saf, 2003, 26(8): 585-588.
[43]Wang Z, Roberts JM, Grant PG, et al. The effect of a medicinal Chinese herb on platelet function[J]. Thromb Haemost, 1982, 48(3): 301-306.
[44]Wu WW, Yeung JH. Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo[J]. Phytomedicine, 2010, 17(3/4): 219-226.
[45]Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity[J]. Life Sci, 2002, 71(13): 1579-1589.
[46]Liu Y, Zhang JW, Li W, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes[J]. Toxicol Sci, 2006, 91(2): 356-364.
[47]Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans[J]. Clin Pharmacol Ther, 2002, 72(3): 276-287.
[48]Kent UM, Aviram M, Rosenblat M, et al. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9[J]. Drug Metab Dispos, 2002, 30(6): 709-715.
[49]Coderre K, Faria C, Dyer E. Probable warfarin interaction with menthol cough drops[J]. Pharmacotherapy, 2010, 30(1): 110.
[50]Dresser GK, Wacher V, Wong S, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo[J]. Clin Pharmacol Ther, 2002, 72(3): 247-255.
[51]Mohammed AM, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects[J]. Br J Pharmacol, 2008, 154(8): 1691-1700.
[52]Booth SL, Madabushi HT, Davidson KW, et al. Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone)[J]. J Am Diet Assoc, 1995, 95(1): 82-83.
[53]Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals[J]. Integr Cancer Ther, 2009, 8(3): 208-227.
[54]Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations[J]. Clin Pharmacol Ther, 1986, 39(1): 15-24.
[55]Zhou L, Wang S, Zhang Z, et al. Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin[J]. J Ethnopharmacol, 2012, 143(2): 648-655.
[56]程娟,李俊,宋珏,等. A771726在大鼠体内肝肠循环的研究[J]. 安徽医科大学学报, 2010,56 (3): 338-341.
[57]Li H, Wang Y, Fan R, et al. The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage[J]. Drug Des Devel Ther, 2016, 10: 2173-2180.
[58]Li H, Zhang C, Fan R, et al. The effects of Chuanxiong on the pharmacokinetics of warfarin in rats after biliary drainage[J]. J Ethnopharmacol, 2016, 193: 117-124.
[59]Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action[J]. Arch Intern Med, 2007, 167(13): 1414-1419.
[60]Beyth RJ, Milligan PE, Gage BF. Risk factors for bleeding in patients taking coumarins[J]. Curr Hematol Rep, 2002, 1(1): 41-49.
[61]Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages[J]. Am J Med, 2007, 120(8): 700-705.
[62]Liu J, Jiang HH, Wu DK, et al. Effect of gene polymorphims on the warfarin treatment at initial stage[J]. Pharmacogenomics J, 2017, 17(1):47-52.
[63]Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy[J]. J Am Coll Cardiol, 2003, 41(9): 1633-1652.
[64]Wittkowsky AK. Factors associated with INR elevation and bleeding complications during Warfarin therapy[J]. Arch Intern Med, 2005, 165(6): 703.
[65]Marcatto LR, Sacilotto L, Darrieux FC, et al. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation[J]. Oncotarget, 2016, 7(34):54194-54199.
[66]Moreau C, Bajolle F, Siguret V, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement[J]. Blood, 2012, 119(3): 861-867.
[67]Self TH, Wallace JL, Sakaan S, et al. Effect of body weight on dose of vitamin K antagonists[J]. South Med J, 2015, 108(10): 637-643.
[68]Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data[J]. N Engl J Med, 2009, 360(8): 753-764.
[69]Pirmohamed M, Kamali F, Daly AK, et al. Oral anticoagulation: a critique of recent advances and controversies[J]. Trends Pharmacol Sci, 2015, 36(3): 153-163.
[70]Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose[J]. N Engl J Med, 2005, 352(22): 2285-2293.
[71]Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9[J]. Pharmacogenetics, 1994, 4(1): 39-42.
[72]Zhao Z, Moghadasian MH. Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: A review[J]. Food Chem, 2008, 109(4): 691-702.
[73]Soucek P, Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms[J]. Xenobiotica, 1992, 22(1): 83-103.
[74]Tadros R, Shakib S. Warfarin--indications, risks and drug interactions[J]. Aust Fam Physician, 2010, 39(7): 476-479. |